雷珠单抗治疗息肉状脉络膜血管病变的疗效观察

发布时间：2019-08-06 21:26

【摘要】：目的:比较玻璃体腔内注射雷珠单抗在不同类型的息肉状脉络膜血管病变治疗中的临床疗效。方法:选取2013-05/2015-05在绍兴市人民医院治疗的63例63眼息肉状脉络膜血管病变患者作为研究对象,根据息肉数的差异分为单息肉组(38例38眼)和多息肉组(25例25眼),两组患者均接受玻璃体腔内注射雷珠单抗治疗,每月1次,连续注射3mo。注射后随访1a,比较两组患者治疗后最佳矫正视力(best corrected visual acuity,BCVA)和中心视网膜厚度(central retinal thickness,CRT)的变化。结果:与多息肉组比较,单息肉组治疗前最大线性直径更大、纤维血管性视网膜色素上皮脱离发生率更低、BCVA更低(P0.05)。治疗后3、6mo,1a单息肉组BCVA明显低于多息肉组(P0.05);单息肉组治疗后3、6mo,1a时BCVA较治疗前均显著下降(P0.05)。单息肉组和多息肉组患者的CRT在治疗后6、12mo有统计学差异(P0.05);单息肉组治疗后3、6mo,1a时CRT均较治疗前低(P0.05),多息肉组治疗后3、6mo的CRT较治疗前低(P0.05)。结论:玻璃体腔内注射雷珠单抗在多息肉型息肉状脉络膜血管病变中治疗效果更好,息肉数量对于评估预后具有重要意义。
[Abstract]:Objective: to compare the clinical efficacy of intravitreal injection of Leizhu monoclonal antibody in the treatment of different types of polypoid choroid vascular diseases. Methods: 63 patients (63 eyes) with polypoid choroid angiopathy treated in Shaoxing people's Hospital were divided into single polyposis group (38 eyes, 38 eyes) and polypolyposis group (25 eyes, 25 eyes) according to the difference of polyposis number. After injection, the changes of best corrected visual acuity (best corrected visual acuity,BCVA) and central retinal thickness (central retinal thickness,CRT) were compared between the two groups. Results: compared with polyposis group, the maximum linear diameter of single polyposis group was larger, the incidence of fibrovascular retinal pigment epithelial detachment was lower, and BCVA was lower than that of polyposis group before treatment (P 0.05). At 3, 6 months after treatment, BCVA in 1a group was significantly lower than that in polyposis group (P 0.05), and BCVA in single polyposis group was significantly lower than that before treatment at 3, 6 months after treatment (P 0.05). The CRT of patients in single polyposis group and polyposis group was significantly different at 6 months and 12 months after treatment (P 0.05), and the CRT in single polyposis group was lower than that before treatment at 3 and 6 months after treatment (P 0.05), and the CRT at 6 months after treatment in polyposis group was lower than that before treatment (P 0.05). Conclusion: intravitreal injection of Leizhu monoclonal antibody is more effective in the treatment of polypolyposis polyposis choroid vascular lesions, and the number of polyps is of great significance in evaluating the prognosis.
【作者单位】：中国浙江省绍兴市人民医院眼科;
【分类号】：R773.4

【相似文献】